^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | exemestane (Aromatase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Excerpt:
Considering ESR1 mutation status within the exemestane group, patients with an ESR1 mutation had worse PFS than ESR1 wild type (Data Supplement; HR, 2.12; 95% CI, 1.18 to 3.81; P = .01).
DOI:
10.1200/JCO.2016.67.3061
